Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine safety and efficacy of Patanase and Astelin in treating the symptoms of non-allergic vasomotor rhinitis (VMR).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Azelastine; Olopatadine Hydrochloride

Criteria

Inclusion Criteria:

• Diagnosis of VMR with at least 2 years of chronic non-allergic rhinitis

• Negative skin tests to a panel of allergens and positive histamine test within last 2 years

• History of symptoms related to defined VMR triggers

Exclusion Criteria:

• Nasal disorder, surgery, or concurrent disease that could interfere with evaluation of study medications

• Bacterial or viral infection within 14 days of first visit. Diagnosis of acute sinusitis within 30 days of first visit

• Chronic use of drugs that can cause rhinitis